A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Planned End Date changed from 1 May 2019 to 1 Feb 2019.
- 27 Sep 2016 New trial record